Revenue: As of FY2026 Q2, the actual value is USD 22 K.

EPS: As of FY2026 Q2, the actual value is USD -0.94, beating the estimate of USD -1.059.

EBIT: As of FY2026 Q2, the actual value is USD -73.5 M.

Cash Position

Celldex Therapeutics, Inc. reported cash, cash equivalents, and marketable securities of $717.6 million as of June 30, 2026, an increase from $451.5 million as of March 31, 2026. This increase was primarily driven by net proceeds of $323.8 million from an April 2026 underwritten public offering, partially offset by $57.4 million in cash used in operating activities during the second quarter of 2026. As of December 31, 2025, cash, cash equivalents, and marketable securities stood at $518,573 thousand.

Revenues

Total revenues for the second quarter of 2026 were $22 thousand, a decrease from $730 thousand in the second quarter of 2025. For the six months ended June 30, 2026, total revenues were $37 thousand, down from $1,424 thousand for the comparable period in 2025. This decrease was primarily attributed to a reduction in services performed under manufacturing and research and development agreements with Rockefeller University.

Operating Expenses

Research and development (R&D) expenses were $67.5 million in the second quarter of 2026, up from $54.2 million in the second quarter of 2025. For the six months ended June 30, 2026, R&D expenses totaled $140.5 million, compared to $106.8 million for the same period in 2025. The increase in R&D expenses was mainly due to higher barzolvolimab clinical trial and contract manufacturing expenses, as well as an increase in employee headcount. General and administrative (G&A) expenses increased to $13.1 million in the second quarter of 2026 from $10.4 million in the second quarter of 2025. For the six months ended June 30, 2026, G&A expenses were $24.6 million, compared to $21.2 million for the comparable period in 2025, primarily due to increased barzolvolimab commercial planning expenses. Total operating expenses were $80,645 thousand for the second quarter of 2026, compared to $64,587 thousand for the second quarter of 2025. For the six months ended June 30, 2026, total operating expenses were $165,095 thousand, up from $128,021 thousand for the same period in 2025.

Operating Loss

Celldex Therapeutics, Inc. reported an operating loss of - $80,623 thousand for the second quarter of 2026, compared to an operating loss of - $63,857 thousand for the second quarter of 2025. For the six months ended June 30, 2026, the operating loss was - $165,058 thousand, an increase from - $126,597 thousand for the six months ended June 30, 2025.

Investment and Other Income, Net

Investment and other income, net, was $7,120 thousand for the second quarter of 2026, slightly down from $7,257 thousand for the second quarter of 2025. For the six months ended June 30, 2026, this figure was $12,870 thousand, compared to $16,201 thousand for the same period in 2025.

Net Loss

Net loss for the second quarter of 2026 was - $73.5 million, compared to a net loss of - $56.6 million for the second quarter of 2025. For the six months ended June 30, 2026, the net loss was - $152.2 million, compared to a net loss of - $110.4 million for the six months ended June 30, 2025.

Balance Sheet Data (as of June 30, 2026, in thousands)

• Assets:
  • Cash, cash equivalents and marketable securities: $717,587
  • Other current assets: $7,344
  • Property and equipment, net: $9,756
  • Intangible and other assets, net: $47,662
  • Total assets: $782,349
• Liabilities:
  • Current liabilities: $61,325
  • Long-term liabilities: $6,460
• Stockholders’ Equity: $714,564

Shares Outstanding

Celldex Therapeutics, Inc. had 78.5 million shares outstanding at June 30, 2026.

Operational Metrics

Barzolvolimab - Chronic Urticarias: Enrollment for the global Phase 3 program in chronic spontaneous urticaria (CSU), consisting of EMBARQ-CSU1 and EMBARQ-CSU2, was completed six months ahead of guidance, with 1,939 patients enrolled across 43 countries and over 500 sites. Celldex Therapeutics, Inc. also initiated a global Phase 3 study in cold urticaria (ColdU) and symptomatic dermographism (SD) in December 2025.

Barzolvolimab - Atopic Dermatitis and Prurigo Nodularis: Enrollment is complete for the Phase 2 study in atopic dermatitis (AD). The Phase 2 study in prurigo nodularis (PN) did not meet primary or key secondary endpoints, leading to its discontinuation, although barzolvolimab demonstrated a favorable safety profile and rapid suppression of circulating tryptase.

CDX-622 – Bispecific SCF & TSLP: Positive first-in-human data from the Phase 1 trial of bispecific CDX-622 demonstrated rapid, profound, dose-dependent, and durable reductions in serum tryptase, indicating tissue mast cell depletion. CDX-622 was well-tolerated across all study parts and dose levels, with no dose-limiting toxicities or related serious adverse events. A Phase 1 proof of mechanism study in mild to moderate asthma was initiated in January 2026, and the company is advancing expansion into additional indications, including allergic rhinitis and food allergy.

Outlook / Guidance

Celldex Therapeutics, Inc. expects topline data from the Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) in September/October 2026, with a Biologics License Application (BLA) submission planned for 2027. The company anticipates topline data from the Phase 2 atopic dermatitis study in late 2026. Celldex Therapeutics, Inc. believes its cash, cash equivalents, and marketable securities as of June 30, 2026, are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.